Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies

Garuda Therapeutics完成5000万美元A-1轮融资，推进现货型血液干细胞疗法的发展

New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases

新资金将加速迦楼罗的快速增长，并为多种严重和危及生命的疾病开发现货型造血干细胞 (HSC) 疗法提供资金。

CAMBRIDGE, Mass., March 4, 2025-- Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company..

马萨诸塞州剑桥市，2025年3月4日——Garuda Therapeutics（Garuda），一家致力于为多种血液疾病开发现成的造血干细胞（HSC）疗法的生物技术公司，今天宣布成功完成了一轮约5000万美元的A-1系列融资。投资方包括奥博资本（OrbiMed）、北极星创投（Northpond Ventures）和鸬鹚资产管理（Cormorant Asset Management），以及来自日本全球专业制药公司协和麒麟（Kyowa Kirin Co., Ltd.）的新战略投资。

This investment underscores the growing need for an immediate, off-the-shelf and cost-effective solution to stem cell transplants. Garuda’s technology enables self-renewing blood stem cells that are durable, human leukocyte antigen (HLA)-compatible, and transgene-free. As the industry’s potential first off-the-shelf offering, Garuda’s technology has the opportunity to address a multitude of unique blood disorders and eliminate dependency on donor blood cells.

这项投资突显了对干细胞移植即时、现成且经济高效的解决方案日益增长的需求。Garuda的技术能够实现持久、人类白细胞抗原（HLA）兼容且不含转基因的自我更新血干细胞。作为行业潜在的首个现成产品，Garuda的技术有机会应对多种独特的血液疾病，并消除对供体血细胞的依赖。

The Series A-1 funding will support the advancement of Garuda's pipeline into the clinic, assembling an experienced team, scaling its in-house manufacturing, and other general operating activities..

A-1轮融资将支持Garuda的产品线向临床推进、组建经验丰富的团队、扩大内部生产能力以及其他一般运营活动。

'We are thrilled to have closed this Series A-1 round,” said Avanish Vellanki, CEO of Garuda Therapeutics. “Garuda’s first off-the-shelf hematopoietic stem cell transplantation candidate has the potential to HLA-match approximately 12% of the global population without the need for a donor. Additional drug candidates, leveraging the same technology, are aimed to grow the HLA-matched eligible patient population to up to half of the global population for treatment of a range of diseases where a reset of bone marrow function is needed.

“我们很高兴完成了这次A-1轮融资，”Garuda Therapeutics首席执行官Avanish Vellanki表示。“Garuda的首个现成造血干细胞移植候选产品有潜力在无需供体的情况下与大约12%的全球人口进行HLA匹配。利用相同技术的其他候选药物旨在将HLA匹配的适用患者群体扩大到全球人口的一半，用于治疗一系列需要重置骨髓功能的疾病。”

This funding will enable us to accelerate clinical development of our novel technology and move us closer to delivering transformative therapies to patients where there is a great medical need.”.

这笔资金将使我们能够加速新型技术的临床开发，让我们更接近于为存在巨大医疗需求的患者提供变革性的治疗方法。

Mr. Vellanki continued, “Our first product candidate will be evaluated in HLA-matched patients with bone marrow failure syndrome and beta thalassemia. We intend to provide additional detail on our emerging pipeline, based on our proprietary technology, as appropriate.”

维兰基先生继续说道：“我们的第一个产品候选物将在HLA匹配的骨髓衰竭综合征和β地中海贫血患者中进行评估。我们打算在适当的时候，基于我们的专有技术，提供关于我们新兴研发管线的更多细节。”

“We are honored to be backing Garuda as they disrupt the market with their innovative readily available, off-the-shelf technology. The Company’s vision for the future of hematopoietic stem cell transplantation without the need for stem cell donors make this a compelling investment opportunity,' said Carl Gordon, Ph.D., C.F.A., Managing Partner at OrbiMed.

“我们很荣幸能够支持迦楼罗，因为他们通过创新的现成技术颠覆市场。该公司对于未来无需干细胞捐赠者的造血干细胞移植的愿景，使这成为一个令人信服的投资机会，”奥比梅德的管理合伙人卡尔·戈登博士、特许金融分析师表示。

.

。

About Garuda Therapeutics

关于迦楼罗治疗公司

Garuda Therapeutics seeks to eliminate the need for stem cell donors for blood stem cell transplants. Garuda’s proprietary off-the-shelf hematopoietic stem cell (HSC) therapies enable self-renewing, HLA compatible and transgene-free HSCs, available immediately for patients. An immediately available, off-the-shelf option for patients could provide much needed strategies in a multitude of blood disorders across oncology, autoimmune indications, rare heme disorders and inborn errors of metabolism by effectively resetting bone marrow function.

Garuda Therapeutics 旨在消除血液干细胞移植对干细胞捐赠者的依赖。Garuda 专有的现成造血干细胞（HSC）疗法能够提供自我更新、HLA 兼容且无转基因的 HSC，患者可立即使用。这种即时可用的现成治疗选择可以通过有效重置骨髓功能，为肿瘤学、自身免疫性疾病、罕见血液疾病及先天性代谢异常等众多血液疾病提供亟需的治疗策略。

https://garudatx.com/.

https://garudatx.com/.

For further information, please contact:

如需更多信息，请联系：

ir@garudatx.com

ir@garudatx.com